I

n a surprise ruling, a federal judge on Thursday sided with Amgen in a patent dispute — effectively banning Sanofi and Regeneron Pharmaceuticals from selling a competing cholesterol drug.

In 30 days, Sanofi and Regeneron will no longer be able to sell their treatment, Praluent, in the US, leaving Amgen’s Repatha as the sole drug of its type on the market.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.